Loading...
Market
50% reduction in adverse events for Intellia's CRISPR treatment by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Peer-reviewed clinical study publications
Story
Intellia's CRISPR Treatment for 36 ATTR-CM Patients Shows Superior Results, Reports High Adverse Events Over 12 Months
Nov 16, 2024, 03:30 PM
Intellia Therapeutics has announced that its CRISPR treatment for transthyretin amyloid cardiomyopathy (ATTR-CM) has outperformed conventional therapies. In a Phase 1 open-label study involving 36 patients, the treatment demonstrated a consistent reduction in serum TTR levels over 12 months. However, the study also reported a high rate of adverse events, attributed to a combination of the patients' advanced underlying conditions and the therapy itself. The median six-minute walk test (6MWT) results indicated a gain over baseline at the 12-month mark, suggesting improved patient outcomes. This development is significant for patients suffering from ATTR-CM, a condition that can lead to severe heart complications.
View original story
Similar markets
80% or less • 25%
81% to 89% • 25%
90% to 95% • 25%
More than 95% • 25%
Successful reduction in serum TTR levels • 25%
High adverse events lead to study halt • 25%
Modifications required for safety • 25%
Study continuation without major issues • 25%
No improvement • 25%
Slight improvement • 25%
Moderate improvement • 25%
Significant improvement • 25%
Yes • 50%
No • 50%
Less than 20% • 25%
20% to 40% • 25%
41% to 60% • 25%
More than 60% • 25%
Successful • 25%
Partially Successful • 25%
Unsuccessful • 25%
No Data Released • 25%